In 2012, newly reported human immunodeficiency virus diagnoses in the European Union /European Economic Area remained stable at around 30,000 cases. Since 2003, cases in men who have sex with men (MSM) aged 20 to 29 years-old doubled, while the proportion of late presenters in this group remained stable. Persistent declines occurred among older MSM age groups, particularly that between 30 and 39 years-old. Interventions targeting younger MSM are needed to prevent a resurgence of the epidemic in Europe.

Since 2008, the European Centre for Disease Prevention and Control (ECDC), together with the World Health Organization (WHO) Regional Office for Europe, has been coordinating an enhanced human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) surveillance for European Union (EU) Member States and European Economic Area (EEA) countries. The 2012 data collection and analysis offered the opportunity to re-examine the distribution and trends of HIV infection by risk and age group.

Human immunodeficiency virus infections in the European Union/European Economic Area

In 2012, a total of 29,381 new HIV diagnoses were reported by 30 EU/EEA countries, resulting in a rate of 5.8 per 100,000 population [1]. When adjusted for reporting delay [2], this figure rises to 30,900 cases and a rate of 6.2 per 100,000 population [1]. Notification rates in men and women were 9.1 and 2.7 per 100,000, respectively, for a male-to-female ratio of 3.2. Among all new HIV diagnoses (29,381), young people aged 15 to 24 years accounted for 11% (3,114) of all the new HIV diagnoses reported. The largest proportion of new diagnoses, however, was observed among 30 to 39 year-olds (33%, 9,782).

Between 2006 and 2012, the overall rate of reported diagnoses in EU/EEA countries decreased by 3% when adjusting for reporting delay (from 6.4 to 6.2 per 100,000 population). During this time, 14 countries reported decreasing rates whereas increases were reported in 16 countries. The highest proportion of new HIV diagnoses in 2012 continued to be reported among men who have sex with men (MSM) (40%, 11,877 cases), followed by heterosexual transmission (34%, 9,944 cases). The latter includes 12% (3,474 cases) of heterosexually-acquired cases originating from sub-Saharan African countries with generalised epidemics. People who inject drugs (PWID) accounted for 6% (1,785 cases) of all HIV cases.

Figure 1

Proportion of men who have sex with men among newly reported male human immunodeficiency virus cases in 2012 in 15 European Union Member States, 2012 (n=11,774)

HIV: human immunodeficiency virus; MSM: men who have sex with men.
Data on CD4 cell count at the time of HIV diagnosis for more than 50% of cases were provided by 19 countries (overall completeness in 2012: 56%). Among these countries 16,150 cases were reported, of which 7,924 (49%) were categorised as 'late presenters' (CD4 cell count less than 350/mm³), including 4,759 (30%) of cases with advanced HIV infection (CD4 <200/mm³). The highest proportion of late presenters was observed among heterosexually-acquired cases (59%, 3,817 of 6,472), especially among those originating from sub-Saharan countries (62%, 1,454 of 2,361), the lowest among cases due to mother-to-child (23%, 18 of 80) and MSM (38%, 2,857 of 7,458) transmission.

**New human immunodeficiency virus diagnoses and late presentation in men who have sex with men in the European Union**

The analysis included data from 15 countries reporting between 2003 and 2012 which had recorded the mode of transmission for more than 50% of their HIV cases and consistently reported CD4 counts for the period from 2003 to 2012. Among males aged 20 to 29 years, the number of cases during this period almost doubled from 1,037 to 1,881 cases (81% increase). However, among very young MSM under 20 years-old, a much smaller group, an even larger increase was observed from 54 to 116 cases. An increase in cases among MSM younger than 29 years-old was also observed at individual country level in the majority of the 15 countries, reflecting the overall increase.

CD4 cell counts were available for 38,463 HIV diagnoses reported among MSM between 2003 and 2012, increasing from 2,149 cases in 2003 to 4,588 in 2012. In 2012, of 4,588 cases acquired through MSM contact, 37% (1,691 cases) were categorised as late presenters and 18% (845 cases) presented with advanced HIV infection. These figures show improvement since 2003, when of 2,149 cases, the proportion of late presenters and cases with advanced infection at the time of HIV diagnosis were 45% (974 cases) and 25% (537 cases), respectively. The largest drop in the proportion of late presenters was among 30 to 39 year-olds (19% in 2003, 406 cases of 2,149, down to 11%, in 2012, 493 of 4,588) (Table). In all other age groups, the proportion of late presentation decreased by 12% from 2003 to 2012.

**Figure 2**

Distribution of newly reported HIV cases through men who have sex with men transmission by year and age group among 15 European Union Member States, 2003–2012 (n=59,992)

Data on CD4 cell count at the time of HIV diagnosis for more than 50% of cases were provided by 19 countries (overall completeness in 2012: 56%). Among these countries 16,150 cases were reported, of which 7,924 (49%) were categorised as 'late presenters' (CD4 cell count less than 350/mm³), including 4,759 (30%) of cases with advanced HIV infection (CD4 <200/mm³). The highest proportion of late presenters was observed among heterosexually-acquired cases (59%, 3,817 of 6,472), especially among those originating from sub-Saharan countries (62%, 1,454 of 2,361), the lowest among cases due to mother-to-child (23%, 18 of 80) and MSM (38%, 2,857 of 7,458) transmission.

**Figure 3**

Proportion of HIV newly reported cases among MSM by age group among 15 European Union Member States, 2003–2012 (n=59,992)

HIV: human immunodeficiency virus; MSM: men who have sex with men.

The data in the Figure originate from 15 European Union Member States, which reported the mode of transmission for more than 50% of their HIV cases and consistently reported CD4 counts for the period from 2003 to 2012. These 15 countries include Austria, Belgium, Cyprus, Denmark, the Czech Republic, Finland, France, Greece, Latvia, Luxembourg, the Netherlands, Portugal, Romania, Slovenia and the United Kingdom.

In the 15 countries included in the analysis, the number of reported HIV diagnoses among MSM increased by 36%, from a total 4,501 cases in 2003 to 6,130 cases in 2012; the number of cases has remained stable since the peak of 6,585 cases in 2008. Trends by age group varied (Figures 2 and 3): among males aged 20 to 29 years, the number of cases during this period almost doubled from 1,037 to 1,881 cases (81% increase). However, among very young MSM under 20 years-old, a much smaller group, an even larger increase was observed from 54 to 116 cases. An increase in cases among MSM younger than 29 years-old was also observed at individual country level in the majority of the 15 countries, reflecting the overall increase.

CD4 cell counts were available for 38,463 HIV diagnoses reported among MSM between 2003 and 2012, increasing from 2,149 cases in 2003 to 4,588 in 2012. In 2012, of 4,588 cases acquired through MSM contact, 37% (1,691 cases) were categorised as late presenters and 18% (845 cases) presented with advanced HIV infection. These figures show improvement since 2003, when of 2,149 cases, the proportion of late presenters and cases with advanced infection at the time of HIV diagnosis were 45% (974 cases) and 25% (537 cases), respectively. The largest drop in the proportion of late presenters was among 30 to 39 year-olds (19% in 2003, 406 cases of 2,149, down to 11%, in 2012, 493 of 4,588) (Table). In all other age groups, the proportion of late presentation decreased by 12% from 2003 to 2012.
presenters among all newly diagnosed HIV cases remained fairly stable.

Discussion and conclusion

The EU/EEA 2012 surveillance data indicate that new HIV infections remain concentrated in key populations at higher risk of HIV infection, such as MSM, heterosexual people originating from high-endemic countries and, to a lesser extent, people who inject drugs. European surveillance data are heavily dependent on national testing strategies, good case-detection and comprehensive reporting of all cases on a national and European level. Reporting the mode of transmission is key to allow the correct interpretation of data and to improve targeted prevention. Unfortunately, stigma and limited access to low-threshold healthcare facilities still hamper the disclosure of sexual preference in many countries [3] and this is likely to result in under-reporting of MSM transmission [4].

The relatively high proportion of late diagnoses in many countries is a worrying indication of delays in accessing HIV testing. Although we found a stable prevalence of late diagnosis among young MSM (20 to 29 years-old), the concomitant increase in absolute numbers of new HIV infections in this age group is worrying as well. A study from an Australian state whereby testing for HIV among MSM was performed, revealed that MSM under the age of 34 years were more likely than older MSM to have never previously been tested for HIV. In 20 cities in the United States (US) awareness of HIV-positive status in 2008 and in 2011 among MSM increased significantly by age [5,6]. A modelling study among MSM based on the Swiss HIV Cohort Study estimated that by the end of 2010, 13.5% of infected MSM were undiagnosed, however they were estimated to account for almost 82% of new infections due to continuing risky sexual behaviour [7], hence the conclusion by the authors that HIV testing needs to be scaled up.

The increases in new HIV infections among young MSM aged 20 to 29 years reported here are similar to findings during the period between 1994 and 2011 in the US and Australia [5,8-10]. In Norway, although an increase in new HIV cases was found to have occurred from 2003 to 2011, no difference in median age (36 years) among these newly diagnosed HIV cases was observed among MSM between 1995 and 2011 [11]. In Australia, Canada, Germany, the Netherlands, the United Kingdom and the US, the weighted median age was even found to have increased from 34 to 36 years between 1996 and 2005 [12]. Studies showing increasing trends in co-infections with other sexually transmitted infections (STIs) [11-14] suggest high levels of sexual risk behaviour among MSM that augments the likelihood of acquiring HIV and hence might be one of the reasons for the increase in young MSM reported here [11-15].

In Australia, increases in new HIV infections, particularly in young MSM, were found to be strongly correlated with increasing trends, since 1998, of MSM younger than 30 years not taking combination antiretroviral therapy (cART) [8]. In Scotland, younger MSM (<25 years-old) increasingly engaged in higher levels of sexual risk behaviour (2 or more partners with unprotected anal intercourse in the previous 12 months) between 2000 and 2002 [16] and which could be a driving factor for the increasing trends.

In the data presented here we saw a decrease in late presenters in 30 to 39 year-old MSM, which supports the hypothesis that testing increased in this age group over the last decade, probably due to increased

| Table |

Percentage of cases reported to have a CD4 cell count <350/mm³ among all MSM HIV cases with known CD4 counts, by age group, among 15 European Union Member States, 2003–2012 (n=59,992)

<table>
<thead>
<tr>
<th>Age group in years</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20</td>
<td>0.47</td>
<td>0.35</td>
<td>0.34</td>
<td>0.20</td>
<td>0.39</td>
<td>0.30</td>
<td>0.25</td>
<td>0.52</td>
<td>0.46</td>
<td>0.39</td>
</tr>
<tr>
<td>20–29</td>
<td>7.72</td>
<td>7.21</td>
<td>8.30</td>
<td>8.64</td>
<td>8.64</td>
<td>8.46</td>
<td>7.59</td>
<td>8.01</td>
<td>8.15</td>
<td>8.65</td>
</tr>
<tr>
<td>30–39</td>
<td>18.89</td>
<td>15.90</td>
<td>16.80</td>
<td>14.77</td>
<td>13.69</td>
<td>14.04</td>
<td>12.33</td>
<td>11.82</td>
<td>12.05</td>
<td>10.75</td>
</tr>
<tr>
<td>40–49</td>
<td>10.75</td>
<td>11.67</td>
<td>10.64</td>
<td>11.92</td>
<td>11.98</td>
<td>11.91</td>
<td>11.93</td>
<td>11.45</td>
<td>10.25</td>
<td>10.09</td>
</tr>
<tr>
<td>&gt;50</td>
<td>7.49</td>
<td>6.93</td>
<td>5.68</td>
<td>5.99</td>
<td>7.34</td>
<td>6.48</td>
<td>6.59</td>
<td>6.54</td>
<td>5.93</td>
<td>6.97</td>
</tr>
<tr>
<td>All</td>
<td>45.32</td>
<td>42.07</td>
<td>41.77</td>
<td>41.52</td>
<td>42.05</td>
<td>41.20</td>
<td>38.69</td>
<td>38.35</td>
<td>36.83</td>
<td>36.86</td>
</tr>
</tbody>
</table>

HIV: human immunodeficiency virus; MSM: men who have sex with men.
The data in the Table originate from 15 European Union Member States, which reported the mode of transmission for more than 50% of their HIV cases and consistently reported CD4 counts for the period from 2003 to 2012.

These 15 countries include Austria, Belgium, Cyprus, Denmark, the Czech Republic, Finland, France, Greece, Latvia, Luxembourg, the Netherlands, Portugal, Romania, Slovenia and the United Kingdom.
awareness among older MSM [6] or changing testing strategies over time. Despite this, access to and uptake of testing still needs to improve as 37% of all new infections in MSM in 2012 presented at a stage where treatment is already needed.

There are several limitations in this analysis and the results presented. First, data submitted over the years are incomplete, particularly for CD4 cell count, and our interpretation might be biased as cases for which no information on CD4-cell count was given might differ from those reported. To overcome this issue, we strictly limited our analysis to those countries which consistently reported the mode of transmission for more than 50% of cases as well as the CD4 cell count in all years analysed. Second, our results are influenced by countries with large numbers of new HIV infections and a concomitant complete reporting of the mode of transmission. Third, surveillance data is prone to delays in reporting and underreporting. In our MSM analysis, we did not take the reporting delay into account and data for 2012 might still underestimate the true picture. This analysis also does not take into account changes in HIV testing strategies and reporting patterns.

In the last decade, the largest increase in new infections has been seen among young MSM. Throughout Europe, HIV counselling and testing services need to be continuously promoted, made more accessible and targeted at key populations at higher risk to ensure earlier diagnosis and initiation of HIV treatment and linkage to care [17]. This will result in improved treatment outcomes and clinical benefits, as well as contribute to preventing or further reducing HIV transmission.

Acknowledgements

We would like to thank National HIV Contact Points from countries participating in the European network for HIV/AIDS surveillance: Austria: Klein Jean Paul; Belgium: Andre Sasse; Bulgaria: Tonka Varleva; Cyprus: Avgi Hadjiiloukas; Czech Republic: Marek Maly; Denmark: Susan Cowan; Estonia: Kristi Küttel; Finland: Kirsi Liitsola; France: Caroline Semaille; Germany: Osamah Hamouda; Greece: Georgios Nikolopoulos; Dimitra Paraska; Hungary: Mária Dudás; Iceland: Haraldur Briem; Ireland: Kate O’Donnell; Italy: Nikolopoulos, Dimitra Paraskeva; Hungary: Mária Dudás; Iceland: Haraldur Briem; Ireland: Kate O’Donnell; Italy: Barbara Suligoi; Latvia: Šarlote Konova; Lithuania: Saulius Caplinskas; Luxembourg: Jean Claude Schmit; Malta: Jackie Maistre Melillo; Netherlands: Eline op de Coul; Norway: Hans Blystad; Poland: Magdalena Rosinska; Portugal: Helena Cortes Martins; Romania: Mariana Mardaescu; Slovakia: Peter Truska; Slovenia: Irena Klavs; Spain: Mercedes Díez Ruiz-Navarro; Sweden: Frida Hansdotter; United Kingdom: Valerie Delpech. We would like also to thank ECDC colleagues for their contributions, especially Chantal Quinten, Phillip Zucs, Denis Coulombier, Johan Giesecke, the TESSy team and Valentina Lazdina.

Conflicts of interest

None declared.

Authors’ contributions

JJ developed the concept of the manuscript, collected and analysed the data, wrote the first draft of the manuscript and responded to reviewer comments. KH contributed to the concept of the manuscript, interpreted the results critically, contributed to writing the manuscript and revised the article to ensure important intellectual content. GS contributed to the concept of the manuscript and analysis, contributed to writing the manuscript and revision of the article. MvL, GL and AA developed the surveillance instrument, critically reviewed the article and provided important feedback on the article. All authors read and approved the final manuscript.

References


